• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    京

    京都桂病院

    Kyoto Katsura Hospital
    EST. 1937
    951论文总数
    1.4万引用总数

    论文量&引用量时间轴

    机构学者

    论文(951)

    年份
    起
    –
    止
    排序
    1Clinical Outcomes of Postoperative Radiotherapy with Regional Nodal Irradiation Excluding Internal Mammary Lymph Nodes in Breast Cancer: a Multi-Institutional Retrospective Analysis
    Kanako Nakatsu, Yuka Ono,Michio Yoshimura,Kimiko Hirata,Chikako Yamauchi,Masakazu Ogura,Takahiro Kishi,Kota Fujii,Shuji Ohtsu,Takashi Sakamoto, Kazuhito Ueki, Kengo Ogura,

    Background Postoperative regional nodal irradiation (RNI) is a standard treatment for breast cancer at high risk of regional recurrence; however, the necessity of including the internal mammary node (IMN) region in the radiation field remains unclear. This study aimed to evaluate treatment outcomes in a large cohort of patients who received postoperative radiotherapy with RNI excluding the IMN region. Methods This study included patients with breast cancer who underwent surgery followed by RNI without IMN irradiation between 2007 and 2018. The primary endpoint was disease-free survival (DFS), and the secondary endpoints were overall survival (OS), breast cancer-specific mortality (BCM), distant metastasis-free survival (DMFS), recurrence patterns, and treatment-related adverse events. Results In total, 799 patients were included. The 5-year DFS, OS, BCM, and DMFS rates were 75.9, 88.3, 9.7, and 77.1%, respectively. Worse outcomes were associated with a higher number of positive lymph nodes and estrogen receptor (ER)-negative disease. Medial/central tumor location and younger age were each significantly associated with poorer outcomes, being associated with worse DFS and DMFS. Bone was the most common recurrence site. ER-negative disease, a higher number of positive lymph nodes, medial/central location, and younger age were significant risk factors for recurrence, particularly distant metastasis. IMN recurrence was rare. Conclusions In this cohort, medial/central tumor location, ER-negative disease, and extensive nodal involvement were associated with poorer outcomes, suggesting that these factors may identify patients who can benefit from IMN irradiation. These findings may serve as important reference data when determining the indication for IMN irradiation on an individual patient basis.

    2026Breast Cancer(2026)引用:26
    引用
    AI阅读
    加入学术空间
    2Clinical Expert Consensus Document on Rotational Atherectomy from the Japanese Association of Cardiovascular Intervention and Therapeutics: Update 2026
    Kenichi Sakakura, Yoshiaki Ito,Yoshisato Shibata,Atsunori Okamura,Yoshifumi Kashima,Shigeru Nakamura,Yuji Hamazaki,Junya Ako,Hiroyoshi Yokoi, Yoshio Kobayashi,Yuji Ikari,Ken Kozuma

    The Task Force on Rotational Atherectomy of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) proposed the expert consensus document to summarize the techniques and evidence regarding rotational atherectomy (RA) in 2020, which was updated in 2023. Because the revascularization strategy to severely calcified lesions has been the hottest topic in contemporary percutaneous coronary intervention (PCI), many literatures related to RA have been published since 2023. Latest advancements have been incorporated in this updated expert consensus document.

    2026Cardiovascular Intervention and Therapeutics(2026)引用:3
    引用
    AI阅读
    加入学术空间
    3Prognostic Impact of Major Pathologic Response after Preoperative Treatment in Resected Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Retrospective Study of 739 Cases.
    Kei Yamane,Kazuyuki Nagai,Takayuki Anazawa,Yosuke Kasai,Asahi Sato,Yu Hidaka, Yumiko Ibi, Toshihiko Masui,Yuichiro Uchida,Kazuhiko Kitaguchi,Shintaro Yagi, Yusuke Okamura,

    OBJECTIVE:We evaluated the prognostic significance and implications of a major pathologic response (MPR) after preoperative treatment for pancreatic ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA:Preoperative treatment is increasingly used for PDAC to improve oncologic outcomes. The pathologic response represents a potential indicator of treatment efficacy; however, its prognostic value in PDAC remains unclear. METHODS:We retrospectively analyzed 739 patients who underwent pancreatectomy for PDAC after preoperative treatment at 21 institutions in Japan. The pathologic response was graded using Evans' classification, with MPR defined as Evans grade III/IV. Survival outcomes and prognostic factors were evaluated, and factors associated with achieving MPR were analyzed to develop a predictive model. RESULTS:MPR was achieved in 11.5% of patients. The MPR group had a significantly longer median overall survival (71.5 vs. 40.9 mo) and recurrence-free survival (55.5 vs. 15.2 mo) than the non-MPR group. Multivariate analysis identified MPR as an independent prognostic factor for overall survival. In the MPR subgroup, neither overall nor recurrence-free survival differed according to adjuvant chemotherapy administration; multivariate analysis did not identify adjuvant therapy as an independent prognostic factor. Predictive factors for achieving MPR included chemoradiotherapy, preoperative duration ≥6 months, normal carbohydrate antigen 19-9 after preoperative treatment, and complete or partial radiologic response. Finally, we developed a simplified predictive model for achieving MPR. CONCLUSIONS:MPR was independently associated with favorable survival in PDAC. The prognostic impact of adjuvant chemotherapy was not observed among patients who achieved MPR, suggesting that MPR may inform individualized postoperative management and warrants prospective validation.

    2026Annals of surgery(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Real-world Effectiveness of Rituximab or Intravenous Cyclophosphamide Versus Non-Use in Patients with Severe Microscopic Polyangiitis and Granulomatosis with Polyangiitis: a Retrospective Cohort Study of J-CANVAS.
    Satoshi Omura,Takashi Kida,Junya Kitai,Takuya Yanagida,Daiki Nakagomi,Yoshiyuki Abe,Makoto Wada,Naoho Takizawa,Atsushi Nomura, Yuji Kukida,Naoya Kondo, Hirosuke Takagi,

    OBJECTIVES:To evaluate the real-world effectiveness of rituximab (RTX) and intravenous cyclophosphamide (IVCY) compared to non-use for remission induction in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). METHODS:This observational study emulated a target trial using data from the Japan Collaborative Registry of ANCA-associated Vasculitis. Patients aged ≥20 years with newly diagnosed or relapsing MPA or GPA (2017-23) were included. RTX or IVCY use within 4 weeks defined the treatment group; others formed the control group. The primary outcome was failure to achieve remission at week 24 (Birmingham Vasculitis Activity Score = 0 and prednisolone ≤ 10 mg/day). Secondary outcomes included a composite of death, kidney failure, and relapse, and serious infection. In inverse probability weighted population, risk ratios were estimated using modified Poisson regression. RESULTS:Among 544 patients (MPA: 413, GPA: 131), 63.6% received RTX or IVCY. The risk ratio for failure to achieve remission was 0.72 (95% CI: 0.61-0.85), and for the composite outcome was 0.57 (95% CI: 0.33-0.97), and for serious infection was 1.03 (95% CI: 0.47-2.25). Results were robust in sensitivity analyses. CONCLUSIONS:RTX and IVCY improved short-term outcomes in MPA and GPA without increasing infection risk, supporting their recommendation as standard therapy.

    2026Modern rheumatology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5WCN26-4690 PR3-ANCA–ASSOCIATED VASCULITIS WITH ELEVATED IgG4 AND RETROPERITONEAL FIBROSIS: A DIAGNOSIS AND THERAPIUTIC CHALLENGE
    RYO MATSUDA, TAKAFUMI MIYAKE, TAKAHIRO YAMAGUCHI,KAZUTOSHI OKUBO, CHISA TAKATA,NAOYA KONDO, HIITOMI MIYATA
    2026Kidney International Reports(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 951 篇论文

    合作机构(100)

    京都大学合作论文 272
    倉敷中央病院合作论文 76
    Osaka Red Cross Hospital,Japanese Red Cross Society, Japan合作论文 68
    京都市立病院合作论文 67
    Tenri Hospital合作论文 62
    Kobe City Medical Center General Hospital合作论文 56
    京都府立医科大学合作论文 54
    Japanese Red Cross Society Wakayama Medical Center,Japanese Red Cross Society, Japan合作论文 51
    近畿大学合作论文 44
    Kyoto Medical Center,National Hospital Organization合作论文 41

    机构统计